Possible Applications of Fecal Microbiota Transplantation in the Pediatric Population: A Systematic Review
- PMID: 40564111
- PMCID: PMC12190698
- DOI: 10.3390/biomedicines13061393
Possible Applications of Fecal Microbiota Transplantation in the Pediatric Population: A Systematic Review
Abstract
Background: The potential therapeutic role of fecal microbiota transplantation (FMT) in various diseases has been thoroughly studied over the last few decades. However, the majority of studies focus on the adult population, therefore, conclusions regarding the application of FMT in the pediatric population are much less clear. This systematic review aims to summarize the research conducted so far on the efficacy and safety of FMT in the pediatric population, assess the quality of the evidence of its effectiveness, and outline the most promising areas for future research. Methods: We performed a systematic literature search from the index date to 8 June 2024 on the Embase, PubMed, and Web of Science databases. One author screened the resulting 121 articles. Eventually, 35 eligible studies that reported FMT use in seven different diseases were identified. Results: All of the studies assessed FMT as a safe procedure without many serious adverse effects. The best-documented application, which is the only one recommended in official guidelines, is recurrent Clostridioides difficile infection. Other disease entities in which the use of FMT has been studied with good clinical effects are inflammatory bowel disease, allergic colitis, autism, Tourette syndrome, and colonization with multi-drug-resistant organisms. However, it should be noted that the majority of studies are cohort and case-control studies, without randomization, which translates into low evidence quality. In one randomized, controlled trial focusing on the effect of FMT on weight loss in obese individuals, a lack of effect was found. Conclusions: While FMT and subsequent iterations of gut microbiota-targeted interventions hold promising therapeutic potential for various disease entities in the pediatric population, the current evidence behind this conclusion is of low quality. Based on current studies, these methods appear to be both effective and safe. However, further randomized clinical trials are necessary, especially within the pediatric population, for which such studies remain scarce.
Keywords: Clostridioides difficile infection; autism spectrum disorders; fecal microbiota transplantation; gut dysbiosis; gut microbiome; inflammatory bowel disease; pediatrics; systematic review.
Conflict of interest statement
The authors report that there are no competing interests to declare.
Similar articles
-
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2. Cochrane Database Syst Rev. 2023. PMID: 37096495 Free PMC article.
-
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948. Health Technol Assess. 2024. PMID: 39367772 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
Cited by
-
Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML-One Step Closer to Personalized Medicine.Biomedicines. 2025 Jul 18;13(7):1761. doi: 10.3390/biomedicines13071761. Biomedicines. 2025. PMID: 40722831 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources